RxDoctor Payments Data

Ossama Al-Assafeen, MD

Internal Medicine · Lebanon, MONPI 1912078452

Payments from drug & device makers

$6,499in general payments, 2019–2025

Across 373 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$680
  • Pfizer$528
  • Lilly USA, LLC$405
  • Abbott$395
  • AstraZeneca$361
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$6,499100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,499 in reported general payments places this provider in the 90th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$226,546
Medicare patients
411
Services billed
5,763

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide302$381,841
OzempicSemaglutide177$232,161
GlyxambiEmpagliflozin/Linagliptin148$149,809
EliquisApixaban134$148,445
Trelegy ElliptaFluticasone/Umeclidin/Vilanter105$105,344
XareltoRivaroxaban122$103,902
JardianceEmpagliflozin47$60,039
TrulicityDulaglutide35$57,703
Breztri AerosphereBudesonide/Glycopyr/Formoterol74$55,203
FarxigaDapagliflozin Propanediol62$47,523
JanuviaSitagliptin Phosphate33$35,917
RybelsusSemaglutide29$31,680
LinzessLinaclotide33$29,105
MyrbetriqMirabegron31$26,481
TradjentaLinagliptin36$24,906

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$405$439,545337 claims
Novo NordiskOzempic, Rybelsus$680$263,840206 claims
Boehringer IngelheimGlyxambi, Jardiance, Tradjenta, Combivent Respimat, Spiriva Respimat$198$252,589264 claims
PfizerEliquis$528$148,445134 claims
GSKTrelegy Ellipta, Arexvy, Anoro Ellipta$242$127,489168 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$361$119,138187 claims
Johnson & JohnsonXarelto$182$103,902122 claims
MerckJanuvia, Janumet$82$49,30148 claims
AbbVieLinzess, Savella$1,624$35,10845 claims
Astellas Pharma US IncMyrbetriq$80$26,48131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Lebanon

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →